Abstract:Objective HHcy is one of the independent risk factors for either cerebrovascular disease or cognitive impairment. The aim of this study is to investigate the relationship between blood Hcy level and early cognitive impairment in small vessel disease (SVD). Methods The data of SVD patients with no dementia from stroke clinic in our hospital for post-stroke follow-up were consecutively collected. The data included demographic information, vascular risk factors (VRFs) spectrum, cognitive assessment results and etc. The fasting blood Hcy was measured within 1 week after enrollment. HHcy was deflned as plasma Hcy level higher than 15 μmol/L. According to the Hcy test results, the patients were divided into HHcy group (Hcy>15?μmmol/L) and normal homocysteine (NHcy) group (Hcy≤15 μmol/L). Multimodal MRI was performed in all patients within 2 weeks after enrollment. The cognitive scores and imaging feature between the two groups were compared. The correlations of Hcy level with cognitive assessment results as well as with the imaging indices were analyzed. Results (1) A total of 81 SVD patients were enrolled in this study, with average age (64.3±7.4) years old, 65 male patients (80.2%) and 50 patients (61.7%) with mild cognitive impairment. (2) 30 patients (37.0%) in HHcy group and 51 ones (63.0%) in NHcy group. There were more smoking patients in HHcy than in NHcy group. There were no signiflcant difference in age, gender, education years between the two groups. (3) There were significant difference in the attention-executive function assessment such as trail making test B (TMT-B) (P=0.016), digital symbol substitution test (DSST) (P=0.013) and forward digital span test (DS-forward) (P=0.029) scores between the two groups. (4) The proportion of moderate to severe periventricular white matter lesions (PV-WMLs) (63.3% vs 39.2%, P=0.018), deep WMLs (60.0% vs 37.3%, P=0.036) and multiple cerebral microbleedings (CMBs) (36.7% vs 17.3%, P=0.047) in HHcy group were higher than those in NHcy group. The blood Hcy level was correlated with PV-WMLs (r=0.227, P=0.041). (5) After adjusting for PV-WMLs score, Hcy level was positively correlated with TMT-B time (r=0.278, P=0.013), negatively correlated with DSST (r=-0.354, P=0.004) and DS-forward (r=-0.366, P=0.001). Conclusions The blood Hcy level in SVD was signiflcantly correlated with attention-executive function and PV-WMLs. The blood Hcy level might be one of the markers of early cognitive impairment in SVD.

High plasma homocysteine levels predict the progression from mild cognitive impairment to dementia

[Relationship Between Plasma Total Homocysteine and Mild Cognitive Impairment in Senile Patients with Type 2 Diabetes].

Homocysteine, white matter hyperintensities, and cognition in healthy elderly people

Low and High Homocysteine Are Associated with Mortality Independent of B Group Vitamins but Interactive with Cognitive Status in a Free-Living Elderly Cohort

Homocysteine is Associated with the Development of Cerebral Small Vessel Disease: Retrospective Analyses from Neuroimaging and Cognitive Outcomes

Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease

Association of Elevated Plasma Total Homocysteine With Dementia With Lewy Bodies: A Case-Control Study

Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men

Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia

Cerebral small vessel disease mediates the association between homocysteine and cognitive function

Plasma homocysteine and longitudinal change in cognitive function among urban adults

[Investigation on Plasma Homocysteine Level and Cognition in Population at High Risk for Stroke in Xi'an].

Study on the Correlation between Blood Homocysteine Level and Cognitive Function in Patients with Cerebrovascular Disease

Increased plasma homocysteine level is associated with executive dysfunction in type 2 diabetic patients with mild cognitive impairment

Effect of Plasma Homocysteine Levels and Mild Cognitive Dysfunction on Elderly Type 2 Diabetes

Homocysteine and Folic Acid: Risk Factors for Alzheimer's Disease—An Updated Meta-Analysis

Hyperhomocysteinemia and Risk of Cognitive Decline: A Meta-Analysis of Prospective Cohort Studies

Associations between elevated homocysteine, cognitive impairment, and reduced white matter volume in healthy old adults

Homocysteine, cerebrovascular disease and brain atrophy

Hyperhomocysteinemia in Alzheimer dementia patients and cognitive decline after 6 months follow-up period

Homocysteine as a risk factor for cognitive impairment in stroke patients